Journal of Ayurveda and Integrative Medicine最新文献

{"title":"Improved anticancer efficacy of plant leaf extracts from homa environment: A preliminary study","authors":"Priya Sharad ,&nbsp;Shireen Masood ,&nbsp;Osaid Masood ,&nbsp;Alka Kumari ,&nbsp;Ulrich Berk ,&nbsp;Monisha Banerjee","doi":"10.1016/j.jaim.2025.101316","DOIUrl":"10.1016/j.jaim.2025.101316","url":null,"abstract":"<div><h3>Background</h3><div>Medicinal plants have been the most important component of agro-ecosystems and the natural environment from the very beginning of life. Air, water, and soil have been significantly contaminated, adversely affecting the production and development of plants. Homa therapy, based on traditional Vedic knowledge, purportedly restores balance to nature and eliminates environmental pollutants. However, this approach must be comprehended in light of current scientific findings.</div></div><div><h3>Objective</h3><div>This study examined the comparative efficacy of leaves extracted from plants in Homa and non-Homa (control) environments for their anticancer potential in a cervical cancer cell line.</div></div><div><h3>Materials and methods</h3><div>The leaves of the selected medicinal plants–<em>Murraya koenigii</em> (curry)<em>, Ocimum sanctum</em> (tulsi)<em>, Aegle marmelos</em> (bael), and <em>Azadirachta indica</em> (neem), were collected from both locations, subsequently dried, and extracted using Soxhlet apparatus. The leaf extracts were examined for cytotoxicity in HeLa cells using the MTT assay. The rate of cell migration was assessed with a wound healing assay. Subsequently, intracellular reactive oxygen species (ROS) generation was evaluated using DCFDA. Additionally, gene expression was checked using quantitative polymerase chain reaction.</div></div><div><h3>Results</h3><div>Our findings indicate that Homa environment plants are significantly (p &lt; 0.05) more effective against cervical cancer, as their IC₅₀ values were comparatively low. The intracellular ROS generation assay demonstrated that Homa environment plants produced more ROS (p &lt; 0.05) in cancer cells than those of non-Homa plants. Moreover, inhibited cell migration was more noticeable (p &lt; 0.05) in Homa plants than non-Homa plants. The genes, <em>SOD1</em>, <em>CAT</em>, and <em>MMP9</em> were found to be significantly (p &lt; 0.05) downregulated in Homa grown leaf extracts. The study's findings offer promising preliminary trends that the Homa farming environment may improve certain plants' therapeutic qualities, including their capability to fight against cancer.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101316"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147947625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of wet cupping therapy with medications versus standard treatment in the management of chronic cases of unspecified low back pain - A randomised controlled clinical trial","authors":"Ramesh Shivappa Killedar ,&nbsp;Pradeep Shahajirao Shindhe ,&nbsp;Vijay Kage ,&nbsp;Rubeen Nadaf ,&nbsp;Mahesh Sattigeri","doi":"10.1016/j.jaim.2026.101319","DOIUrl":"10.1016/j.jaim.2026.101319","url":null,"abstract":"<div><h3>Background</h3><div>Unspecified chronic lowback pain (UCLBP) is the most common musculoskeletal condition associated with substantial health and socioeconomic problem. UCLBP does not have a known patho-anatomical origin, thus treatment focuses on minimizing pain and its consequences. Education and reassurance, medications, nonpharmacological therapy, and timely review are all part of the management strategy.</div></div><div><h3>Objective</h3><div>To evaluate the efficacy of Wet Cupping Therapy with Medications versus Standard treatment in the management of chronic cases of unspecified Low Back Pain.</div></div><div><h3>Materials and methods</h3><div>134 participants of either sex, aged between 20 and 70 years, diagnosed with UCLBP were recruited for the study. The participants were divided into trial and standard group by computer generated random number software method. Trial group received two sittings of wet-cupping therapy and medications for 14 days. Control group received TENS and HMP for 7 days, acetaminophen 500 mg twice daily and exercise therapy for 14 days. Assessments of primary and secondary outcome variables were done on day 7, day 14 and follow up was done on day 21 and day 28. Inflammatory biomarkers like TNF alpha and IL 6 were analysed using ELISA. Statistical analysis was done with Chi-square test, Mann Whitney <em>U</em> test, Friedman's ANOVA and Wilcoxon matched pair test to assess the significance between and within group results.</div></div><div><h3>Results</h3><div>Significant results were observed (p &lt; 0.05) in all the assessed outcome variables like VAS, NPRS, VRS, <em>Stambha</em> (stiffness), <em>Gourava</em> (heaviness)<em>,</em> Suptata (numbness) Range of motions, Modified Oswestry disability index, Roland-Morris disability questionnaire, TNF-alpha and IL6, Quality of life assessed by SF-36 questionnaire in within group results at various time points. Comparable results were seen in between group results, in all the assessed outcome variables.</div></div><div><h3>Conclusion</h3><div>Wet Cupping therapy along with medications was effective in managing the UCLBP, improved quality of life, reduced disability and inflammatory biomarkers.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101319"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147995984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tapentadol and Zolpidem addiction management with Ayurvedic intervention: A case report","authors":"Priyanka Katru,&nbsp;Anshul Narula,&nbsp;Anita Sharma","doi":"10.1016/j.jaim.2026.101327","DOIUrl":"10.1016/j.jaim.2026.101327","url":null,"abstract":"<div><div>Opioids pose significant challenges worldwide. Tapentadol's unrestrained availability has raised concerns, as it is developing as an alternative for illicit pharmaceutical opioids. A case of 31-year-old patient complaining of anxiousness, profuse perspiration, body ache, lacrimation, restlessness, sleeplessness, and loose stools with history of Tapentadol and zolpidem abuse showed in the OPD on Oct 31, 2023. The patient's Clinical opiate withdrawal scale (COWS) evaluated withdrawal symptoms of the as moderate (score 28) and the Insomnia Severity Index (ISI) showed the severe insomnia (score 25). Patient was prescribed with tapering dose of <em>Sameergajakesari Rasa</em> (375, 250, 125mg), <em>Vishatindukadi Vati</em> 250mg<em>,</em> Combination of <em>Sitopaladi Churna</em> 3g + <em>Lakshmivilas Rasa</em> 250mg + <em>Tankan Bhasma</em> 250 mg, over 3 weeks, Combination of <em>Vaatvidhwansank Ras</em> 250mg + <em>Godanti Bhasma</em> 250mg + <em>Tryodshang Gugglu</em> 500mg for first 2 weeks, <em>Ksheerpaka</em> of <em>Ashwagandha Churna</em> 3g + <em>Shatavari Churna</em> 2g + <em>Gokshur Churna</em> 1g and <em>Brahmarasayan</em> 5g for third week. Externally <em>Dashmoola Tail Sarvanga Abhyanga, Sarvanga Swedana, Shirodhara</em> with <em>Til Taila</em> and <em>Brahmi Tail, Pranayama, Yoga</em> and counselling<em>.</em> The total COWS score decreased from 28 prior to treatment to 2 after three weeks of treatment. Similarly, ISI score decreased from 25 to zero after treatment. The patient was treated solely using Ayurvedic treatment, including <em>Satvajaya Chikitsa,</em> and no complications were noticed during the course of treatment. Observations suggested that with the Ayurvedic management, withdrawals and insomnia were completely resolved within three weeks of treatment. The baseline investigations were normal, and the patient continued to practice yoga and counselling during and after therapy, abstaining for 60 days post treatment.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101327"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the regulatory landscape of herbal medicines: A global comparison of India, China, Europe, the United States and Japan","authors":"Anil Tukaram Pawar ,&nbsp;S.B. Chandrasekar ,&nbsp;M.P. Venkatesh","doi":"10.1016/j.jaim.2026.101343","DOIUrl":"10.1016/j.jaim.2026.101343","url":null,"abstract":"<div><div>The use of herbal medicines is expanding rapidly worldwide, but regional regulatory systems vary greatly, leading to variations in quality, safety and efficacy. Varying legal frameworks, insufficient quality control and gaps in post-market surveillance create challenges in ensuring the reliability of herbal products. This study aims to analyze and compare the regulations that oversee herbal medicines in five major regions: India, China, Europe, the United States and Japan, highlighting key challenges and proposing recommendations for improving global regulatory alignment. Data were collected from official regulatory websites and scholarly articles. Additionally, the study tracked the progress of related regulations, advancements in scientific research, and the evolving infrastructure in the respective five geographical areas. The study examined regulatory components, including licensing requirements, pre-market validation, quality control and post-market surveillance across these five regions. Regulatory approaches vary significantly: Europe and Japan emphasize pre-market validation and scientific evidence, while the U.S. relies more on post-market monitoring. India and China integrate traditional practices with modern regulatory frameworks. These differences pose challenges for ensuring consistent safety and quality standards globally. Potential solutions involve adopting Good Manufacturing Practices (GMPs), harmonizing pharmacopoeial standards and leveraging emerging technologies such as artificial intelligence for quality assurance and supply chain transparency. Achieving global regulatory harmonization is crucial for ensuring the safety and efficacy of herbal medicines while preserving traditional knowledge. Strengthening international collaboration, enforcing standardized quality measures, and integrating scientific validation into traditional systems can enhance consumer confidence and facilitate international trade in herbal medicines.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101343"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148030726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of integrative therapy of Drakshavaleha with oral iron folic acid supplements in management of mild to moderate iron deficiency anaemia in women of reproductive age group- A protocol for a parallel group randomized controlled trial","authors":"Manish J. Barvaliya ,&nbsp;Kalesh M. Karun ,&nbsp;M.S. Chandrashekar ,&nbsp;N. Chandan ,&nbsp;Harsha V. Hegde ,&nbsp;Sandeep S. Sagare ,&nbsp;Ravikumar BS ,&nbsp;Subarna Roy","doi":"10.1016/j.jaim.2026.101352","DOIUrl":"10.1016/j.jaim.2026.101352","url":null,"abstract":"<div><h3>Background</h3><div>Adding <em>Drakshavaleha</em> to iron-folic acid (IFA) supplementation could lead to a significant increase in hemoglobin (Hb) levels compared to IFA alone due to its bioavailability-enhancing property. This paper presents a protocol for the randomized controlled trial (RCT) assessing the efficacy and safety of integrating <em>Drakshavaleha</em> with IFA supplementation in improving hemoglobin levels among women aged 18-49 years with mild to moderate iron-deficiency anaemia.</div></div><div><h3>Methods</h3><div>This parallel-group, open-label, community-based randomized controlled trial will include women aged 18 to 49 years with mild (Hb 11-11.9 g/dL) to moderate (Hb 8-10.9 g/dL) iron deficiency anaemia. Consecutive participants meeting the inclusion/exclusion criteria will be enrolled after providing written informed consent and randomly assigned to one of two groups in a 1:1 ratio using block randomization. The control group will receive 200 mg of ferrous sulphate and 0.5 mg of folic acid orally, twice daily after food for 3 months. The intervention group will receive 6 g of <em>Drakshavaleha</em> orally, twice daily before food, in addition to the same IFA dosage as the control group. Participants will be followed up monthly at 1, 2 and 3 months. At all follow-up visits, CBC and iron profiles will be done whereas serum creatinine, serum bilirubin, serum glutamic pyruvic aminotransferase (SGPT), and HbA1C will be done at 3 months.</div></div><div><h3>Conclusion</h3><div>This protocol outlines the RCT to assess the efficacy and safety of integrating <em>Drakshavaleha</em> with IFA supplements and explore <em>Drakshavaleha</em>'s role in enhancing assimilation of oral iron from supplements and nutrition.</div></div><div><h3>Trial registration number</h3><div>The trial is registered in Clinical Trials Registry - India (CTRI) under registration number CTRI/2024/05/067169.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101352"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147995904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Illustration of Kleda concept in “common soil hypothesis” context","authors":"H.S. Mythri ,&nbsp;R. Nithin Krishnan","doi":"10.1016/j.jaim.2023.100752","DOIUrl":"10.1016/j.jaim.2023.100752","url":null,"abstract":"<div><div><em>Kleda</em> is one of the important but least explored concepts of Ayurveda. The term <em>Kleda</em> literally means ‘dampness/moisture’. <em>Kleda</em> plays an essential role in maintaining the physiology and manifesting diseases when imbalanced. It is the fundamental constituent in the pathogenesis of diseases associated with <em>Pitta</em> and <em>Kapha Dosha</em>. ‘Common soil hypothesis’ explains regarding the common prevailing substrate which is invariably involved in the manifestation of several Metabolic Disorders. There are several candidates for ‘common soil’, such as insulin resistance, vascular inflammation, and endothelial dysfunction, possessing oxidative stress and chronic inflammation as centrally participating mechanisms in all stages of diseases. This article presents a complete review on understanding Common soil hypothesis on the grounds of <em>Kleda</em> and <em>Santarpanottha Vyadhi</em> (diseases arising due to over nourishment). This review of the concept of <em>Kleda</em> has been outlined to foreground the necessity of a holistic approach in promotion of health, prevention, and management of variants of Metabolic disorders which sprout from the unified soil of <em>Kleda</em>.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 100752"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147928980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tongue coating, severity of Ama, and disease activity in patients with Rheumatoid Arthritis: A pilot study","authors":"Shrikant Wagh ,&nbsp;Vinayak Joshi ,&nbsp;Ashwinikumar A. Raut ,&nbsp;Sanjeev Rastogi ,&nbsp;Digambar Deepankar ,&nbsp;Srikanth Babu Perugu ,&nbsp;Madhavi Mahajan","doi":"10.1016/j.jaim.2025.101315","DOIUrl":"10.1016/j.jaim.2025.101315","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Tongue examination has been documented in Ayurveda and other medical systems. The severity of tongue coating (TC), an indicator of &lt;em&gt;Ama&lt;/em&gt; in Ayurveda, can be clinically assessed by the Winkel tongue coating index (WTCI) through the analysis of smartphone images. This pilot study examines the relationship between TC and disease severity, as well as TC and &lt;em&gt;Ama&lt;/em&gt; severity, in patients with Rheumatoid Arthritis (RA), a prototype of Amavata.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;Consecutive outpatients suffering from RA (diagnosed as per ACR/EULAR criteria, 2010) were divided into two groups- Group A: Treatment naïve patients with active disease, and Group B: patients on treatment in remission as determined by Clinical Disease Activity Index (CDAI). The &lt;em&gt;Ama&lt;/em&gt;-severity in these subjects was assessed by a validated &lt;em&gt;Ama&lt;/em&gt;-instrument. A photograph of the tongue obtained by a smartphone was selected, edited, and marked into sextants for WTCI assessment. These photographs were randomized and submitted for TC analysis to five expert clinicians. Eleven images in each group could be analysed by all assessors. The clinical records of the respective patients were used for statistical analysis (GraphPad InStat Version 3.6 software).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Twenty-two cases, 11 with active, untreated RA (Group A), and 11 in remission (Group B), were studied. All patients were females except one. Patients in Group A were older, less educated, and had a lower BMI than those in Group B. There was moderate inter-rater agreement (0.76 in Group A and 0.73 in Group B). There was no significant correlation between CDAI and WTCI (Spearman r = −0.08356, &lt;em&gt;P&lt;/em&gt; = 0.7116, 95 % CI = −0.4981 - 0.3621) as well as between &lt;em&gt;Ama&lt;/em&gt; Score and WTCI (Spearman r = - 0.1608, &lt;em&gt;P&lt;/em&gt; = 0.4748, 95 % CI = −0.5548 - 0.2921). However, the Bonferroni correction indicated a statistically significant association between WTCI and the &lt;em&gt;Ama&lt;/em&gt;-score. Moreover, the Friedman test revealed maximum coating in the posterior-middle area (area B, Fr = 57.728; &lt;em&gt;P&lt;/em&gt; = &lt; 0.0001, 95 % CI 1.645 to 1.937). Also, a moderately positive correlation between the TC score in area B and &lt;em&gt;Ama-&lt;/em&gt;score (Spearman r = 0.4790, &lt;em&gt;P&lt;/em&gt; = 0.0241, 95 % CI = 0.05858–0.7551) as well as between TC Score in area B and CDAI (r = 0.4393, &lt;em&gt;P&lt;/em&gt; = 0.0408, 95 % CI = 0.008332 to 0.7327) was observed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;This pilot study indicates that there is a positive association between WTCI and &lt;em&gt;Ama&lt;/em&gt;-score in &lt;em&gt;Amavata&lt;/em&gt; (RA). A moderately positive correlation between the severity of TC in the posterior-middle area and the severity of &lt;em&gt;A&lt;/em&gt;&lt;em&gt;ma&lt;/em&gt; in &lt;em&gt;Amavata&lt;/em&gt; (RA) implies a careful examination of the posterior tongue in these patients. The inter-observer reliability was moderate during this study. Studies with a larger sample size are recommended based on observa","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101315"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147952001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of tariff on Indian AYUSH products: Evidence from top importers of India","authors":"Saravanan Sengunthar,&nbsp;Diganta Sarkar,&nbsp;Pravin Jadhav","doi":"10.1016/j.jaim.2026.101329","DOIUrl":"10.1016/j.jaim.2026.101329","url":null,"abstract":"<div><div><strong><u>Background</u></strong> The global demand for Indian AYUSH (Ayurveda, Yoga &amp; Naturopathy, Unani, Siddha, and Homeopathy) products has been rising, yet the impact of tariff reduction on their trade remains largely unexplored.</div><div><strong><u>Objective</u></strong> This study aims to assess the effects of tariff reduction on AYUSH product exports to eight major importing countries, which collectively account for approximately 50% of India's AYUSH exports.</div><div><strong><u>Methods</u></strong> The analysis covers 19 eight-digit HS codes specified by AYUSHEXCIL, which include traditional AYUSH products along with related cosmetic and dental preparations that contain herbal and traditional medicine ingredients, as dedicated six-digit HS codes for pure AYUSH products are not available in the international trade classification system. Using secondary trade data, the research employs a Partial Equilibrium Analysis through the Trade Intelligence and Negotiation Advisor (TINA) model to simulate trade scenarios under reduced tariff conditions.</div><div><strong><u>Results</u></strong> The findings indicate that while tariff reductions generally enhance trade, a blanket zero-tariff policy across all AYUSH products is not advisable. In certain product categories, trade diversion outweighs trade creation, leading to potential welfare losses for India.</div><div><strong><u>Conclusion</u></strong> The study provides critical insights for policymakers, suggesting a selective tariff reduction strategy that maximizes trade benefits while safeguarding national economic interests.<u>The findings underscore the importance of integrating product-specific competitiveness, regulatory harmonization, and upstream value chain considerations into India's AYUSH export strategy</u></div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101329"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147995902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the relationship between Ayurgenomics and bio-psycho-social symptoms in cancer care","authors":"Padmashanti Nilachal ,&nbsp;Ananda Balayogi Bhavanani ,&nbsp;Uthpala Gajamanne ,&nbsp;Vandana Srivastava ,&nbsp;Karthikeyan Kaliyamurthi","doi":"10.1016/j.jaim.2026.101321","DOIUrl":"10.1016/j.jaim.2026.101321","url":null,"abstract":"<div><h3>Background</h3><div>Ayurveda, the ancient Indian system of medicine, emphasises the role of individual constitution in health. Modern Ayurgenomics integrates Ayurvedic principles with genomic analysis, aiming to personalize Yogic interventions for cancer patients.</div></div><div><h3>Objective</h3><div>The current study aims to explore the intersection of Ayurgenomics, <em>d</em><em>eha</em> <em>p</em><em>rakriti</em>, and Yoga Therapy in the context of medical oncology.</div></div><div><h3>Method</h3><div>The study included 60 chemotherapy patients, with their <em>d</em><em>eha</em> <em>p</em><em>rakriti</em> assessed using AyuSoft. Patients' symptoms were diagnosed with the Rotterdam Symptom Checklist (RSCL). The data was analyzed to observe any correlation between Prakriti type and chemotherapy response.</div></div><div><h3>Results</h3><div><em>Vatapradhan</em> types show high physical impairment (38.96) but retain functionality (13.83). <em>Pittapradhan</em> types have minimal physical burden (24.05) but high psychological strain (13.00) with a positive life outlook. <em>Kapha</em>-dominant types experience moderate physical (27.78–34.61) and psychological burdens (9.69–12.12) and slower disease progression. Major findings revealed that <em>v</em><em>ata</em>-dominant patients required more immediate intervention due to rapid tumor growth, while <em>p</em><em>itta</em>-dominant patients were more susceptible to chemotherapy side effects. Patients with <em>k</em><em>apha</em> <em>p</em><em>rakriti</em> showed slower tumor growth. Appropriate Yogic interventions and dietary adjustments may help manage the loss of vitality during chemotherapy.</div></div><div><h3>Conclusion</h3><div>The study highlights the growing relevance of integrating traditional Eastern wisdom, such as <em>Ayurveda</em>, with Western scientific approaches to personalize cancer care. Integrating Prakriti-based Yogic interventions may alleviate the physical and psychological impact of cancer and its treatments, enhancing the overall quality of life for patients.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101321"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic effects of Ghrita Manda Ashchyotana on tear film stability, corneal integrity, and IL-6 expression in a benzalkonium chloride-induced murine dry eye model","authors":"Ramya Shruthi Janardhanan,&nbsp;Sivabalaji Kundrinmani,&nbsp;Ashwini Belludi Nagaraj","doi":"10.1016/j.jaim.2026.101354","DOIUrl":"10.1016/j.jaim.2026.101354","url":null,"abstract":"<div><h3>Background</h3><div>Dry Eye (DE) is a condition marked by tear film instability and chronic inflammation, leading to visual impairment. Conventional artificial tears often contain preservatives that exacerbate DE and fail to address underlying tissue damage. In <em>Ayurveda,</em> DE symptoms corelates with <em>S</em><em>ushkakshipaka</em>, managed by normalizing <em>vata pitta</em> derangement. This study evaluates the mechanism of <em>Ghrita Manda</em> <em>Ashchyotana</em> in a Benzalkonium Chloride (BAC)-induced murine dry eye model.</div></div><div><h3>Methodology</h3><div>12 male Swiss albino mice (24 eyes) were divided into: saline-treated controls (3 mice), and dry eye-induced mice treated with either <em>Ghrita Manda</em> (Trial), preservative-free eye drops (Positive control), or left untreated (Negative control). Assessments included Tear Film Break-Up Time (TFBUT), fluorescein scores, corneal Hematoxylin and Eosin (H&amp;E) staining, and IL-6 expression after 14 days.</div></div><div><h3>Results</h3><div><em>Ghrita Manda</em> significantly improved TFBUT and reduced fluorescein scores compared to the negative control (p &lt; 0.001). Corneal integrity was preserved without hyperplasia in the trial group. A notable reduction in IL-6 expression was observed compared to the positive control.</div></div><div><h3>Conclusion</h3><div><em>Ghrita Manda</em> demonstrates potential as an effective DE therapy, offering lubrication, corneal protection, and anti-inflammatory benefits, aligning with <em>Ayurvedic</em> principles for managing <em>vata pitta</em> derangements of the ocular surface.</div></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"17 3","pages":"Article 101354"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148042363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}